Find Clinical Trial

Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. Study assessInG the morbi-mortality beNefits of the If inhibitor ivabradine in patients with coronary arterY disease (SIGNIFY)


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationCoronary Artery Disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

IVABRADINE,
S016257

Active Substance CodeS016257
Protocol CodeCL3-16257-083
EudraCT Code2009-011360-10
NCT CodeNCT02446990
ISRCTN CodeISRCTN61576291


Documents and links

Results summary READ MORE
First scientific publication READ MORE
Second scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility